The DOI matches its Crossref record; 88 of the 89 references it cites were found in a registry or an index, and 1 are not checked yet.
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Open accessAbstract
AIMS/HYPOTHESIS: Diabetes treatments were related with either an increased or reduced risk of cancer. There is ongoing debate about a potential protective action of metformin. To summarize evidence on the association between metformin and risk of cancer and cancer mortality in patients with diabetes. DATA SOURCE: MEDLINE and EMBASE (January 1966-April 2012). We selected randomized studies comparing metformin and other hypoglycaemic agents and observational studies exploring the association between exposure to metformin and cancer. Outcomes were cancer mortality, all malignancies and site-specific cancers. RESULTS: Of 25307 citations identified, 12 randomized controlled trials (21,595 patients) and 41 observational studies (1,029,389 patients) met the inclusion criteria. In observational studies there was a significant association of exposure to metformin with the risk of cancer death [6 studies, 24,410 patients, OR:0.65, 95%CI: 0.53-0.80], all malignancies [18 studies, 561,836 patients, OR:0.73, 95%CI: 0.61-0.88], liver [8 studies, 312,742 patients, OR:0.34; 95%CI: 0.19-0.60] colorectal [12 studies, 871,365 patients, OR:0.83, 95%CI: 0.74-0.92], pancreas [9 studies, 847,248 patients, OR:0.56, 95%CI: 0.36-0.86], stomach [2 studies, 100701 patients, OR:0.83, 95%CI: 0.76-0.91], and esophagus cancer [2 studies, 100694 patients, OR:0.90, 95%CI: 0.83-0.98]. No significant difference of risk was observed in randomized trials. Metformin was not associated with the risk of: breast cancer, lung cancer, ovarian cancer, uterus cancer, prostate cancer, bladder cancer, kidney cancer, and melanoma. CONCLUSIONS/INTERPRETATION: Results suggest that Metformin might be associated with a significant reduction in the risk of cancer and cancer-related mortality. Randomized trials specifically designed to evaluate the efficacy of metformin as an anticancer agent are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“long-term use of metformin in type 2 diabetes patients has been linked to a decline in tumor incidence and a reduced rate of cancer-related deaths.192–196”
From Drug repurposing for cancer therapy (2024) · cites this paper as [193]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, retrospective clinical studies have found that metformin use is associated with improved cancer outcomes, reductions in cancer incidence, and decreased cancer mortality (Evans et al., 2005; Franciosi et al., 2013; Gandini et al., 2014; Lee et al., 2012; Noto et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Franciosi et al., 2013
In the citing paper
“this finding has subsequently been confirmed in several other studies(7–10).”
In the citing paper
“Originally introduced for the treatment of diabetes, metformin is now gaining attention as a potential anti-cancer agent (7–10) (Figure 1).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J., Green, S. R., & Higgins, J. (2008) · Cited by 5,544
Cochrane Handbook for Systematic Reviews of Interventions
Tarsilla, M. (2010) · Journal of MultiDisciplinary Evaluation · doi:10.56645/jmde.v6i14.284 · Cited by 5,232
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Case-Control Studies: Design, Conduct, Analysis.
Youkeles, L., & Schlesselman, J. J. (1983) · Journal of the American Statistical Association · doi:10.2307/2288156 · Cited by 2,358
Drug delivery with carbon nanotubes for in vivo cancer treatment
Liu, Z., Chen, K., Davis, C. R., Sherlock, S. P., Cao, Q., Chen, X. S., & Dai, H. (2008) · PubMed · doi:10.48550/arxiv.0808.2070 · Cited by 2,287
Research works printed but not linked: 1
- S Jiralerspong, 2009, Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breastcancer, J Clin Oncol, 27, 3297, 10.1200/JCO.2009.19.6410 · DOI · Paper page
Cited by
Sorted by citations
Items 101–200 of 430
Health Benefits of Anti-aging Drugs
Piskovatska, V., Strilbytska, O. M., Koliada, A. K., Vaiserman, A. M., & Lushchak, O. V. (2019) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-981-13-3681-2_13 · Cited by 62
Effect of metformin on the incidence of head and neck cancer in diabetics
Yen, Y.-C., Lin, C., Lin, S.-W., Lin, Y., & Weng, S. (2014) · Head & Neck · doi:10.1002/hed.23743 · Cited by 59
Mechanisms of metformin inhibiting cancer invasion and migration.
Chen, Y. C., Li, H., & Wang, J. (2020) · PubMed · Cited by 64
Repurposing old drugs to chemoprevention: the case of metformin
Heckman‐Stoddard, B. M., Gandini, S., Puntoni, M., Dunn, B. K., DeCensi, A., & Szabo, E. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.009 · Cited by 61
Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling.
Chen, G., Feng, W., Zhang, S., Bian, K., Yan, Y., Fang, C., Chen, M., Yang, J., & Zou, X. (2015) · Europe PMC (PubMed Central) · Cited by 58
Diabetes mellitus increases the risk of colorectal neoplasia: An updated meta-analysis
Luo, S., Li, J., Zhao, L., Yu, T., Zhong, W., Xia, Z., Shan, T., Ouyang, H., Yang, H., & Chen, Q. (2015) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2015.05.021 · Cited by 58
Association of Gestational Diabetes With Subsequent Long-Term Risk of Mortality
Wang, Y., Mitsunami, M., Manson, J. E., Gaskins, A. J., Rich-Edwards, J. W., Wang, L., Zhang, C., & Chavarro, J. E. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.4401 · Cited by 58
Tseng, C. (2021) · Biomolecules · doi:10.3390/biom11071022 · Cited by 55
Metformin, an Old Drug, Brings a New Era to Cancer Therapy
He, H., Ke, R., Lin, H., Ying, Y., Liu, D., & Luo, Z. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000103 · Cited by 55
Min, X., Wang, Y., Ren, Q., & Guo, Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.033 · Cited by 55
The Use of Metformin to Increase the Human Healthspan
Piskovatska, V., Storey, K. B., Vaiserman, A. M., & Lushchak, O. V. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-42667-5_13 · Cited by 55
de Bruijn, K. M. J., Ruiter, R., de Keyser, C. E., Albert Hofman, D., Stricker, B. H. C., & van Eijck, C. H. J. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.06.019 · Cited by 55
Rao, M., Gao, C., Guo, M., Law, B. Y. K., & Xu, Y. (2018) · Cancer Management and Research · doi:10.2147/cmar.s174535 · Cited by 54
Delhaye, M., Steenbergen, W. V., Cesmeli, E., Pelckmans, P. A., Putzeys, V., Roeyen, G., Berrevoet, F. C., Scheers, I., Ausloos, F., Gast, P., et al. (2014) · PubMed · Cited by 53
Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation
Farmer, R. E., Ford, D., Forbes, H. J., Chaturvedi, N., Kaplan, R. S., Smeeth, L. L., & Bhaskaran, K. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw275 · Cited by 53
Lam, B., Shrivastava, S. K., Shrivastava, A., Shankar, S., & Srivastava, R. K. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15413 · Cited by 53
Epidemiology of Hepatocellular Carcinoma
El‐Serag, H. B. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch59 · Cited by 53
Associations between Diabetes Mellitus and Selected Cancers
Pliszka, M., & Szablewski, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137476 · Cited by 53
Targeting ovarian cancer stem cells: a new way out
Ma, H., Tian, T., & Cui, Z. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03244-4 · Cited by 51
An update of research evidence on nutrition and prostate cancer
Lin, P., Aronson, W. J., & Freedland, S. J. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.10.006 · Cited by 51
Bahrambeigi, S., & Shafiei‐Irannejad, V. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113787 · Cited by 51
Papavasileiou, G. E., Tsilingiris, D., Spyrou, N., Vallianou, N. G., Karampela, Ι., Magkos, F., & Dalamaga, Μ. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.03.002 · Cited by 51
Heterogeneity of glycolysis in cancers and therapeutic opportunities
Warmoes, M. O., & Locasale, J. W. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.019 · Cited by 50
Gong, Z., Aragaki, A. K., Chlebowski, R. T., Manson, J. E., Rohan, T. E., Chen, C., Vitolins, M. Z., Tinker, L. F., LeBlanc, E. S., Kuller, L. H., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29944 · Cited by 50
Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy
Ezewuiro, O., Grushko, T. A., Kocherginsky, M., Habis, M., Hurteau, J. A., Mills, K. A., HUNN, J., Olopade, O. I., Fleming, G. F., & Romero, I. L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147145 · Cited by 51
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
Sui, X., Xu, Y., Yang, J., Fang, Y., Lou, H., Han, W., Zhang, M., Chen, W., Wang, K., Li, D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097781 · Cited by 50
Androgen receptor variation affects prostate cancer progression and drug resistance
McCrea, E. M., Sissung, T. M., Price, D. K., Chau, C. H., & Figg, W. D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.10.001 · Cited by 49
Huang, W., Sundquist, J., Sundquist, K., & Ji, J. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.05.012 · Cited by 49
Metformin and improved treatment outcomes in radiation therapy – A review
Samsuri, N. A. B., Leech, M., & Marignol, L. H. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.03.005 · Cited by 47
Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L. (2019) · Cancers · doi:10.3390/cancers11071014 · Cited by 46
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth
Tsutsumi, Y., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Terawaki, Y., Tanaka, T., Murase, K., Motonaga, R., Tanabe, M., & Yanase, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139709 · Cited by 47
Fujihara, S., Kato, K., Morishita, A., Iwama, H., Nishioka, T., Chiyo, T., Nishiyama, N., Miyoshi, H., Kobayashi, M., Kobara, H., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2903 · Cited by 47
Cardel, M., Jensen, S. M., Pottegård, A., Jørgensen, T. L., & Hallas, J. (2014) · Cancer Medicine · doi:10.1002/cam4.306 · Cited by 47
Dankner, R. S., Agay, N., Olmer, L., Murad, H., Keinan‐Boker, L., Balicer, R. D., & Freedman, L. S. (2019) · American Journal of Epidemiology · doi:10.1093/aje/kwz157 · Cited by 46
Chen, H.-H., Lin, M., Muo, C., Yeh, S.-Y., Sung, F., & Kao, C. (2015) · Medicine · doi:10.1097/md.0000000000001013 · Cited by 46
Perez-Lopez, F. R., Pasupuleti, V., Gianuzzi, X., Palma-Ardiles, G., Hernandez-Fernandez, W., & Hernandez, A. V. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.04.001 · Cited by 45
Park, J., Cho, S. Y., Jeong, S., Lee, S. B., Son, H., & Jeong, H. (2015) · British Journal of Urology · doi:10.1111/bju.13206 · Cited by 45
Liu, Z., Qi, S., Ζhao, X., Li, M., Ding, S., Lü, J., & Zhang, H. (2016) · Oncotarget · doi:10.18632/oncotarget.7040 · Cited by 45
Risk factors for cancer development in type 2 diabetes: A retrospective case-control study
Dąbrowski, M., Szymańska‐Garbacz, E., Miszczyszyn, Z., Dereziński, T., & Czupryniak, L. (2016) · BMC Cancer · doi:10.1186/s12885-016-2836-6 · Cited by 45
Cho, M. H., Yoo, T. G., Jeong, S., & Shin, D. W. (2020) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0123 · Cited by 45
Shi, J., Liu, B., Wang, H., Zhang, T., & Yang, L. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2018-000060 · Cited by 44
Cerullo, M., Gani, F., Chen, S. Y., Canner, J., & Pawlik, T. M. (2016) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-016-3173-4 · Cited by 43
Bergamini, C., Leoni, I., Rizzardi, N., Melli, M., Galvani, G., Coadǎ, C. A., Giovannini, C., Monti, E., Liparulo, I., Valenti, F., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02718-w · Cited by 42
Expanding the therapeutic spectrum of metformin: from diabetes to cancer
Coperchini, F., Leporati, P., Rotondi, M., & Chiovato, L. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0370-z · Cited by 43
Repurposing metformin for the treatment of gastrointestinal cancer
Júnior, A. D. D. C., Bragagnoli, A. S. C., Costa, F. O., & Carvalheira, J. B. C. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i17.1883 · Cited by 42
Metformin and lung cancer risk of patients with type 2 diabetes mellitus: A meta-analysis
Zhu, N., Zhang, Y., Gong, Y., He, J., & CHEN, X. (2015) · Biomedical Reports · doi:10.3892/br.2015.417 · Cited by 41
Metformin: Metabolic Rewiring Faces Tumor Heterogeneity
Cioce, M., Pulito, C., Strano, S., Blandino, G., & Fazio, V. M. (2020) · Cells · doi:10.3390/cells9112439 · Cited by 41
Rosato, V., Tavani, A., Gràcia‐Lavedan, E., Guinó, E., Castaño‐Vinyals, G., Villanueva, C. M., Kogevinas, M., Polesel, J., Serraino, D., Pisa, F. E., et al. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00210 · Cited by 40
A review for clinicians: Prostate cancer and the antineoplastic properties of metformin
Hankinson, S. J., Fam, M. M., & Patel, N. N. (2016) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.10.009 · Cited by 40
Antitumor effect of metformin on cholangiocarcinoma: In vitro and in vivo studies
Fujimori, T., Kato, K., Fujihara, S., Iwama, H., Yamashita, T., Kobayashi, K., Kamada, H., Morishita, A., Kobara, H., Mori, H., et al. (2015) · Oncology Reports · doi:10.3892/or.2015.4284 · Cited by 41
Lennon, F. E., Cianci, G. C., Kanteti, R., Riehm, J., Arif, Q., Poroyko, V. A., Lupovitch, E., Vigneswaran, W. T., Husain, A. N., Chen, P., et al. (2016) · Scientific Reports · doi:10.1038/srep24578 · Cited by 41
Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis
Ratziu, V., Ghabril, M., Romero‐Gómez, M., & Svegliati‐Baroni, G. (2018) · Transplantation · doi:10.1097/tp.0000000000002483 · Cited by 40
Diabetes mellitus and endometrial carcinoma: Risk factors and etiological links
Wang, Y., Zeng, X., Tan, J., Xu, Y., & Yi, C. (2022) · Medicine · doi:10.1097/md.0000000000030299 · Cited by 37
Walker, E. J., Ko, A. H., Holly, E. A., & Bracci, P. M. (2014) · International Journal of Cancer · doi:10.1002/ijc.29120 · Cited by 37
Association of diabetes and diabetes treatment with incidence of breast cancer
García‐Esquinas, E., Guinó, E., Castaño‐Vinyals, G., Pérez‐Gómez, B., Llorca, J., Altzibar, J. M., Peiró, R., Martín, V., Moreno-Iribas, C., Tardón, A., et al. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0756-6 · Cited by 37
Current state and outlook for drug repositioning anticipated in the field of ovarian cancer
Kobayashi, Y., Banno, K., Kunitomi, H., Tominaga, E., & Aoki, D. (2018) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2019.30.e10 · Cited by 37
Yang, W., Shin, H., Cho, H., Chung, J., Lee, E., Kim, J., & Kang, E. (2020) · Cancers · doi:10.3390/cancers12051329 · Cited by 37
Kumar, A., Al-Sammarraie, N., DiPette, D. J., & Singh, U. S. (2014) · Oncotarget · doi:10.18632/oncotarget.2606 · Cited by 38
Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer
Paulus, J. K., Williams, C. D., Cossor, F. I., Kelley, M. J., & Martell, R. E. (2016) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0312 · Cited by 38
Anti-tumor effects of metformin on head and neck carcinoma cell lines: A systematic review
Rêgo, D. F., Elias, S. T., Amato, A. A., Canto, G. D. L., & Guerra, E. N. S. (2016) · Oncology Letters · doi:10.3892/ol.2016.5526 · Cited by 37
Metformin Intervention—A Panacea for Cancer Treatment?
Buczyńska, A., Sidorkiewicz, I., Kretowski, A. J., Zbucka-Krętowska, M., & Adamska, A. (2022) · Cancers · doi:10.3390/cancers14051336 · Cited by 37
Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis
Qi, C., Li, B., Yang, Y., Yang, Y., Li, J., Zhou, Q., Wen, Y.-X., Zeng, C., Zheng, L., Zhang, Q., et al. (2016) · Scientific Reports · doi:10.1038/srep27819 · Cited by 36
Psutka, S. P., Boorjian, S. A., Lohse, C. M., Stewart, S. B., Tollefson, M. K., Cheville, J. C., Leibovich, B. C., & Thompson, R. H. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.07.008 · Cited by 36
Kang, S., Kim, B. R., Kang, M. H., Kim, D. Y., Lee, D.-H., Oh, S. C., Min, B. W., & Um, J. W. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205449 · Cited by 36
Colon neoplasia in patients with type 2 diabetes on metformin: A meta-analysis
Rokkas, T., & Portincasa, P. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.05.027 · Cited by 34
Dickerman, B. A., García‐Albéniz, X., Logan, R. W., Denaxas, S., & Hernán, M. Á. (2023) · Epidemiology · doi:10.1097/ede.0000000000001626 · Cited by 36
The exposome and pancreatic cancer, lifestyle and environmental risk factors for PDAC
Peduzzi, G., Archibugi, L., Farinella, R., Pisani, R. P. D. L., Vodičková, Ľ., Vodička, P., Kraja, B., Sáinz, J., Bars‐Cortina, D., Daniel, N., et al. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.05.004 · Cited by 35
Medairos, R. A., Clark, J., Holoubek, S. A., Kubasiak, J., Pithadia, R., Hamid, F., Chmielewski, G. W., Warren, W. H., Basu, S., Borgia, J. A., et al. (2016) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2016.03.094 · Cited by 34
A Retrospective Study on the Role of Diabetes and Metformin in Colorectal Cancer Disease Survival
Ramjeesingh, R., Orr, C., Bricks, C. S., Hopman, W. M., & Hammad, N. (2016) · Current Oncology · doi:10.3747/co.23.2809 · Cited by 34
Seo, Y.-S., Kim, Y.-J., Kim, M., Suh, K., Kim, S. B., Han, C. J., Kim, Y. J., Jang, W. I., Kang, S. H., Tchoe, H. J., et al. (2016) · Medicine · doi:10.1097/md.0000000000003527 · Cited by 34
Fan, H., Yu, X., Zou, Z., Zheng, W., Deng, X., Guo, L., Jiang, W. B., Zhan, Q., & Lu, S. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy160 · Cited by 34
Barbieri, F., Verduci, I., Carlini, V., Zona, G., Pagano, A., Mazzanti, M., & Florio, T. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00135 · Cited by 34
Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review
Zhang, Y., Zhou, F., Guan, J., Zhou, L., & Chen, B. (2023) · Biomolecules · doi:10.3390/biom13020250 · Cited by 38
MATE2 Expression Is Associated With Cancer Cell Response to Metformin
Chowdhury, S., Yung, E., Pintilie, M., Muaddi, H., Chaib, S., Yeung, M., Fusciello, M., Sykes, J., Pitcher, B., Hagenkort, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165214 · Cited by 33
Dave, P. N., Macwan, P. M., & Kamaliya, B. P. (2023) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2023.131815 · Cited by 33
Senescent cells as a target for anti-aging interventions: From senolytics to immune therapies
Fu, T., & Zhou, Z. (2025) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2025-0005 · Cited by 35
Metformin blocks progression of obesity-activated thyroid cancer in a mouse model
Park, J., Kim, W. G., Zhao, L., Enomoto, K., Willingham, M. C., & Cheng, S.-Y. (2016) · Oncotarget · doi:10.18632/oncotarget.8989 · Cited by 34
Review of Associations Between Type 2 Diabetes and Cancer
Bonagiri, P. R., & Shubrook, J. H. (2020) · Clinical Diabetes · doi:10.2337/cd19-0077 · Cited by 32
Metformin, Microbiome and Protection Against Colorectal Cancer
Jones, G. R. D., & Molloy, M. P. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06390-4 · Cited by 33
Rossor, M. N., & Knapp, M. R. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60248-3 · Cited by 34
Li, P., Zhang, C., Gao, P., Chen, X., Ma, B., Yu, D., Song, Y., & Wang, Z. (2017) · Oncology Letters · doi:10.3892/ol.2017.7370 · Cited by 32
Wang, Y., Liu, X., Yan, P., Tang, J., Chen, T., Sun, Y., Zhou, W., Bi, Y., & Zhang, Z.-J. (2019) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000514 · Cited by 32
UCA1 involved in the metformin-regulated bladder cancer cell proliferation and glycolysis
Li, T., Sun, X.-Z., & Jiang, X. (2017) · Tumor Biology · doi:10.1177/1010428317710823 · Cited by 32
Holden, S. E., Jenkins‐Jones, S., & Currie, C. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153594 · Cited by 31
Montaudié, H., Cerezo, M., Bahadoran, P., Roger, C., Passeron, T., Machet, L., Arnault, J., Verneuil, L., Maubec, E., Aubin, F., et al. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12576 · Cited by 31
Metformin protects against mouse oocyte apoptosis defects induced by arecoline
Li, W., Zang, C., Yin, S., Shen, W., Sun, Q., & Zhao, M. (2020) · Cell Proliferation · doi:10.1111/cpr.12809 · Cited by 31
Júnior, A. D. D. C., Pericole, F. V., & Carvalheira, J. B. C. (2018) · Clinics · doi:10.6061/clinics/2018/e412s · Cited by 32
Vicentini, M., Ballotari, P., Rossi, P. G., Venturelli, F., Sacchettini, C., Greci, M., Mangone, L., Pezzarossi, A., & Manicardi, V. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.04.036 · Cited by 30
Shin, C. M., Kim, N., Han, K., Kim, B., Jung, J., Oh, T. J., & Lee, D. H. (2019) · Cancer Epidemiology · doi:10.1016/j.canep.2019.101658 · Cited by 30
Is this the end for ranitidine? NDMA presence continues to confound
Wagner, J. A., Dinh, J., Lightdale, J. R., Gold, B. D., & Colombo, J. M. (2021) · Clinical and Translational Science · doi:10.1111/cts.12995 · Cited by 30
Use of Antihyperglycemic Drugs and Risk of Cancer in Patients with Diabetes
Søndergaard, C. S., Esquivel, P. N., Dalamaga, Μ., & Magkos, F. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01344-7 · Cited by 33
Powe, C. E., Tobias, D. K., Michels, K. B., Chen, W. Y., Eliassen, A. H., Manson, J. E., ROSNER, B. A., Willett, W. C., Hu, F. B., Zhang, C., et al. (2016) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0601 · Cited by 30
Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention
Seabloom, D. E., Galbraith, A. R., Haynes, A. M., Antonides, J. D., Wuertz, B. R. K., Miller, W. A., Miller, K. A., Steele, V. E., Miller, M. S., Clapper, M. L., et al. (2017) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-16-0232 · Cited by 30
Joo, M. K., Park, J., & Chun, H. J. (2017) · Digestive Diseases · doi:10.1159/000480149 · Cited by 30
Recycling the Purpose of Old Drugs to Treat Ovarian Cancer
Nunes, M., Abreu, M. H., Bartosch, C., & Ricardo, S. A. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207768 · Cited by 29
Mathews Samuel, S., Satheesh, N. J., Ghosh, S., Büsselberg, D., Majeed, Y., Ding, H., & Triggle, C. R. (2019) · Cancers · doi:10.3390/cancers11111737 · Cited by 28
Yamana, H., Kato, K., Kobara, H., Fujihara, S., Fujita, K., Namima, D., Fujita, N., Kobayashi, K., Kamada, H., Morishita, A., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13933 · Cited by 28
Metformin: On Ongoing Journey across Diabetes, Cancer Therapy and Prevention
Pulito, C., Sanli, T., Rana, P., Muti, P. C., Blandino, G., & Strano, S. (2013) · Metabolites · doi:10.3390/metabo3041051 · Cited by 27
Diabetes Mellitus Type 2: A Driving Force for Urological Complications
Sayyid, R. K., & Fleshner, N. E. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.02.006 · Cited by 27
Metadata
- Authors
- Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G. F. M., Pellegrini, F., & Nicolucci, A.
- Affiliations
- University of Naples Federico II (IT)
- The University of Sydney (AU)
- Corresponding author
- Franciosi, Monica
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-08-02
- Volume
- 8
- Issue
- 8
- Pages
- e71583
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3732236
- OpenAlex
- W2081540191
- Cited by
- 428
- References
- 89
- Citations by year
- 2026: 8 · 2025: 18 · 2024: 19 · 2023: 27 · 2022: 18 · 2021: 29 · 2020: 31 · 2019: 36 · 2018: 31 · 2017: 44 · 2016: 51 · 2015: 59 · 2014: 52 · 2013: 5
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- type 2 diabetes, cancer risk, cancer mortality, liver cancer, colorectal cancer, pancreatic cancer, gastric cancer, esophageal cancer, site-specific cancer, chemoprevention, antidiabetic drugs, drug safety, randomized controlled trials, observational studies, breast cancer, lung cancer, ovarian cancer, prostate cancer, bladder cancer, kidney cancer, melanoma
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Neoplasms, Risk Factors, Meta-Analysis as Topic, Randomized Controlled Trials as Topic, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
